Clinical Trial Update: Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder [Phase 2]

View source ↗

Summary

A Phase 2 inpatient trial of buprenorphine induction with psilocybin for opioid use disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• Psilocybin (psilocybin)
• buprenorphine (buprenorphine)

Snippet

Sponsor: Johns Hopkins University | Conditions: Opioid Use Disorder | Phase 2 | Status: WITHDRAWN